Macchiarini P, Fontanini G, Hardin J M, Pingitore R, Angeletti C A
Service of Thoracic Surgery, University of Pisa, Italy.
J Thorac Cardiovasc Surg. 1992 Oct;104(4):892-9.
We investigated the tumor aggressiveness (intratumoral and peritumoral lymphatic and blood vessel invasion by tumor emboli) and proliferative activity (mitotic count) of 45 patients with peripheral, superficially seated, node-negative (T1-2 N0 M0), non-small-cell lung cancer treated with wedge resection alone between January 1982 and June 1988. Most patients were male (n = 39) with T1 (n = 25), small (mean diameter, 2.6 +/- 0.8 cm), squamous (n = 24), right-sided (n = 29) tumors located in either upper lobe (n = 35). The surgical specimens were studied by immunohistochemical staining with a monoclonal antibody targeting the factor VIII-related antigen. None of the tumors had lymphatic peritumoral or intratumoral invasion. Seven neoplasms (15%) harbored blood vessel invasion by tumor cells; all but one of these invasions were within the substance of the tumor. The median mitotic count was 8 mitoses per 10 high-power fields (range, 1 to 42 mitoses), significantly (p = 0.003) higher in patients with blood vessel invasion than in those without. With a 24-month minimum follow-up, projected 3- and 5-year survivals are 79% and 68%, respectively. Eleven patients had relapses and died of their tumors because of either local (n = 5) or extrathoracic (n = 6) recurrence; three patients died without tumors of comorbidity. Among the six tumors recurring in extrathoracic sites, five (83%) harbored intratumoral (n = 4) or peritumoral (n = 1) blood vessel invasion. Both recurrence of disease and death from non-small-cell lung cancer were significantly (p = 0.0009) higher for tumors with blood vessel invasion. By univariate analysis, significant predictors of survival were tumor stage (T1 vs T2, p = 0.008), size (< or = 2.6 cm vs > 2.6 cm, p = 0.039), mitotic count (< or = 8 vs > 8 mitoses, p = 0.0007), and blood vessel invasion (absence vs presence, p = 0.0001). By multivariate analysis, however, only blood vessel invasion retained its level of prognostic significance (p = 0.006). Data demonstrate that peripheral, node-negative non-small-cell lung cancers have a low metastatic potential. Whenever anatomically feasible, wedge resection seems to be an appropriate method of primary treatment.
我们调查了1982年1月至1988年6月间仅接受楔形切除术治疗的45例周围型、浅表性、淋巴结阴性(T1-2 N0 M0)非小细胞肺癌患者的肿瘤侵袭性(肿瘤栓子引起的瘤内和瘤周淋巴管及血管侵犯)和增殖活性(有丝分裂计数)。大多数患者为男性(n = 39),肿瘤为T1期(n = 25),体积较小(平均直径2.6 +/- 0.8 cm),为鳞状细胞癌(n = 24),位于右侧(n = 29),且位于上叶(n = 35)。手术标本采用针对因子VIII相关抗原的单克隆抗体进行免疫组化染色研究。所有肿瘤均无瘤周或瘤内淋巴管侵犯。7例肿瘤(15%)存在肿瘤细胞血管侵犯;除1例侵犯外,其余侵犯均在肿瘤实质内。有丝分裂计数中位数为每10个高倍视野8个有丝分裂(范围为1至42个有丝分裂),血管侵犯患者的有丝分裂计数显著高于无血管侵犯患者(p = 0.003)。随访至少24个月,预计3年和5年生存率分别为79%和68%。11例患者复发并死于肿瘤,原因是局部复发(n = 5)或胸外复发(n = 6);3例患者因合并症而非肿瘤死亡。在6例胸外复发的肿瘤中,5例(83%)存在瘤内(n = 4)或瘤周(n = 1)血管侵犯。血管侵犯的肿瘤疾病复发和非小细胞肺癌死亡均显著更高(p = 0.0009)。单因素分析显示,生存的显著预测因素为肿瘤分期(T1期与T2期,p = 0.008)、肿瘤大小(≤2.6 cm与>2.6 cm,p = 0.039)、有丝分裂计数(≤8个有丝分裂与>8个有丝分裂,p = 0.0007)和血管侵犯(无与有,p = 0.0001)。然而,多因素分析显示,只有血管侵犯保留了其预后意义水平(p = 0.006)。数据表明,周围型、淋巴结阴性非小细胞肺癌转移潜能较低。只要解剖学上可行,楔形切除术似乎是一种合适的初始治疗方法。